Roth Capital Downgrades vTv Therapeutics (VTVT) to Neutral
Tweet
Share
E-mailGet Alerts VTVT Hot Sheet
Price: $32.90 --0%
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Join SI Premium – FREE
Roth Capital downgraded vTv Therapeutics (NASDAQ: VTVT) from Buy to Neutral with a price target of $1.00 (from $17.00).
For an analyst ratings summary and ratings history on vTv Therapeutics click here. For more ratings news on vTv Therapeutics click here.
Shares of vTv Therapeutics closed at $3.26 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
- Seaport Global Securities Upgrades Analog Devices (ADI) to Buy, 'appears to be entering the sweet part of the cycle'
- Giant Biogene Holding Co (2367:HK) PT Raised to HK$46 at Macquarie
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
